N
← Back to Search
Sponsored

Accelerate Your Clinical Trial Recruitment

Reach thousands of high-intent patients matching your specific inclusion criteria.

Start Campaign
RECRUITING Phase 1 ClinicalTrials.gov

A Study of GSK5764227 in Combination With Standard of Care (SoC) or Other Agents in Participants With Advanced Solid Tumors

Sponsor: GlaxoSmithKline • ClinicalTrials.gov ID: NCT07277270

Registry updated: 2026-09-25
Ad

Recruiting for Similar Conditions?

Sponsors are looking for patients like you. See if you qualify for compensated research studies.

Check Eligibility →

Description

The goal of this clinical trial is to test a new medicine called GSK5764227, which delivers a toxin directly to cancer cells to destroy them while sparing healthy cells. The study will combine GSK5764227 with standard treatments to evaluate its safety, examine how the body processes it, check if it triggers any immune responses, and assess whether it can shrink or control cancer.

Interventions

  • GSK5764227 (Drug)
    Participants will receive GSK5764227.
  • Bevacizumab (Drug)
    Participants will receive bevacizumab.
  • Fluorouracil (Drug)
    Participants will receive fluorouracil.
  • leucovorin (Drug)
    Participants will receive leucovorin.
  • Enzalutamide (Drug)
    Participants will receive enzalutamide.

Eligibility criteria

Inclusion Criteria: * Has an ECOG performance status of 0 or 1, with no deterioration in the 2 weeks before first dose. * Has adequate organ function. * Has histologically confirmed unresectable adenocarcinoma or unresectable metastatic adenocarcinoma of the colon or rectum. (Cohort A) * Histologically or cytologically confirmed adenocarcinoma of the prostate (Cohort B) Exclusion Criteria: * Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas \[e.g., breast, cervix, bladder\] that have been resected with no evidence of disease. * Has had any major surgery within 28 days prior to first dose. * Has clinically significant bleeding symptoms or significant bleeding tendency within 1 month prior to the first dose. * Has serious infection within 4 weeks prior to the first dose, * Has untreated brain or central nervous system (CNS) metastases or brain/CNS metastases that have progressed * Any evidence of current interstitial lung disease (ILD) or pneumonitis OR a prior history of ILD requiring high-dose glucocorticoids or non-infectious pneumonitis requiring high-dose glucocorticoids. * Has a history of autoimmune disease that has required systemic treatments in the 2 years prior to screening. * Has received immunosuppressive agents within 30 days prior to first dose of study intervention (or requires long-term \[30 days or longer\]). Low-dose corticosteroids (prednisone ≤10 milligrams (mg)/day or equivalent) may be administered.

Conditions

Neoplasms

Locations

  • GSK Investigational Site — Reunion, Florida, United States
  • GSK Investigational Site — New Hyde Park, New York, United States
  • GSK Investigational Site — Philadelphia, Pennsylvania, United States
  • GSK Investigational Site — Nashville, Tennessee, United States
  • GSK Investigational Site — Dallas, Texas, United States
  • GSK Investigational Site — Douglas, Queensland, Australia
  • GSK Investigational Site — Tugun, Queensland, Australia
  • GSK Investigational Site — Geelong, Victoria, Australia
  • GSK Investigational Site — Bendigo, Australia
  • GSK Investigational Site — Ottawa, Ontario, Canada
  • GSK Investigational Site — Toronto, Ontario, Canada
  • GSK Investigational Site — Seoul, South Korea
  • GSK Investigational Site — Seoul, South Korea
  • GSK Investigational Site — Seoul, South Korea
  • GSK Investigational Site — Barcelona, Spain
  • GSK Investigational Site — Madrid, Spain
  • GSK Investigational Site — Madrid, Spain
  • GSK Investigational Site — Madrid, Spain
  • GSK Investigational Site — Málaga, Spain
  • GSK Investigational Site — Leicester, United Kingdom
  • GSK Investigational Site — London, United Kingdom
  • GSK Investigational Site — Sutton, United Kingdom
Sponsored

Partner with Nurenyx

Showcase your study to thousands of motivated patients matching your criteria.

Learn More

Official Source

Data sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

View Official Record